Oliver A Cornely

Summary

Country: Germany

Publications

  1. doi request reprint European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, University of Cologne, ZKS Köln, Germany Centre for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases CECAD, German Centre for Infection Research, Cologne, Germany
    Clin Microbiol Infect 20:1-4. 2014
  2. ncbi request reprint Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin
    Oliver A Cornely
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 31:2493-9. 2013
  3. doi request reprint Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    O A Cornely
    1st Department of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Center for Integrated Oncology CIO Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases and German Centre for Infection Research, University of Cologne, Cologne, Germany
    Clin Microbiol Infect 18:28-35. 2012
  4. ncbi request reprint ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Center for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany
    Clin Microbiol Infect 18:19-37. 2012
  5. pmc Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin
    Oliver A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Germany
    Clin Infect Dis 55:S154-61. 2012
  6. ncbi request reprint Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
    Oliver A Cornely
    University Hospital Cologne, Cologne, Germany
    Lancet Infect Dis 12:281-9. 2012
  7. pmc Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
    Oliver A Cornely
    Department I for Internal Medicine, University Hospital Cologne, ZKS Köln BMBF 01KN1106, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 56:2652-8. 2012
  8. doi request reprint Current experience in treating invasive zygomycosis with posaconazole
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, University of Cologne Hospital, Cologne, Germany
    Clin Microbiol Infect 15:77-81. 2009
  9. pmc Phase II dose escalation study of caspofungin for invasive Aspergillosis
    O A Cornely
    1st Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Antimicrob Agents Chemother 55:5798-803. 2011
  10. ncbi request reprint Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections
    O A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50924, Cologne, Germany
    Infection 36:296-313. 2008

Detail Information

Publications88

  1. doi request reprint European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, University of Cologne, ZKS Köln, Germany Centre for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases CECAD, German Centre for Infection Research, Cologne, Germany
    Clin Microbiol Infect 20:1-4. 2014
    ..phaeohyphomycosis (Alternaria, Bipolaris, Cladosporium, Rhinocladiella, etc.), and emerging yeasts (Saccharomyces, Trichosporon, Rhodotorula, etc.). ..
  2. ncbi request reprint Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin
    Oliver A Cornely
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Clin Oncol 31:2493-9. 2013
    ..Patients with cancer are at increased risk for Clostridium difficile-associated diarrhea (CDAD). Little is known about treatment response...
  3. doi request reprint Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    O A Cornely
    1st Department of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Center for Integrated Oncology CIO Köln Bonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases and German Centre for Infection Research, University of Cologne, Cologne, Germany
    Clin Microbiol Infect 18:28-35. 2012
    ..Fidaxomicin has a safety profile similar to oral vancomycin and appears generally well tolerated. Fidaxomicin represents an important addition to current treatment options for CDI...
  4. ncbi request reprint ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Center for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany
    Clin Microbiol Infect 18:19-37. 2012
    ..Amphotericin B deoxycholate is not recommended for any indication due to severe side effects...
  5. pmc Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin
    Oliver A Cornely
    Department I of Internal Medicine, Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, Germany
    Clin Infect Dis 55:S154-61. 2012
    ..003). In patients with a first recurrence of CDI, fidaxomicin was similar to vancomycin in achieving a clinical response at end of therapy but superior in preventing a second recurrence within 28 days...
  6. ncbi request reprint Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
    Oliver A Cornely
    University Hospital Cologne, Cologne, Germany
    Lancet Infect Dis 12:281-9. 2012
    ..We aimed to compare efficacy and safety of fidaxomicin and vancomycin to treat patients with C difficile infection in Europe, Canada, and the USA...
  7. pmc Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection
    Oliver A Cornely
    Department I for Internal Medicine, University Hospital Cologne, ZKS Köln BMBF 01KN1106, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 56:2652-8. 2012
    ..A change in dosing regimen on day 9 did not lead to higher exposures in these "poor absorbers" on day 15. Poor absorption may be enhanced with a high-fat meal, a nutritional supplement, or acidification...
  8. doi request reprint Current experience in treating invasive zygomycosis with posaconazole
    O A Cornely
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, University of Cologne Hospital, Cologne, Germany
    Clin Microbiol Infect 15:77-81. 2009
    ..If impaired kidney function is overt or expected on the grounds of, for example, uncontrolled diabetes, primary treatment of zygomycosis with posaconazole is an option...
  9. pmc Phase II dose escalation study of caspofungin for invasive Aspergillosis
    O A Cornely
    1st Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    Antimicrob Agents Chemother 55:5798-803. 2011
    ..Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin...
  10. ncbi request reprint Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections
    O A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50924, Cologne, Germany
    Infection 36:296-313. 2008
    ..Knowledge of the pathogenesis of IFIs and the activity, efficacy, and limitations of available treatment options will allow the selection of an appropriate antifungal agent for individual patients...
  11. doi request reprint Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease
    Oliver A Cornely
    Department I of Internal Medicine, Infectious Diseases, University of Cologne, Cologne, Germany
    Mycoses 54:e449-55. 2011
    ..As possible invasive mould disease probably reflects an early-stage of disease, a better outcome might be expected when treatment with liposomal amphotericin B is started preemptively...
  12. ncbi request reprint Caspofungin for the treatment of less common forms of invasive candidiasis
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50924 Köln, Germany
    J Antimicrob Chemother 60:363-9. 2007
    ..Caspofungin has demonstrated efficacy in invasive candidiasis. However, in a comparative study, most patients (>83%) had candidaemia. Therefore, we performed a study in patients with non-fungaemic invasive candidiasis...
  13. doi request reprint Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B
    O A Cornely
    Klinik I für Innere Medizin and Zentrum für Klinische Studien, Universitat zu Koln, Germany
    J Antimicrob Chemother 65:114-7. 2010
    ..To analyse the potential antagonism between azoles, which inhibit ergosterol synthesis, and polyenes, which bind directly to ergosterol in cell membranes, in patients receiving sequential azole-polyene treatment...
  14. pmc Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
    Oliver A Cornely
    Klinikum der Universität zu Köln, Klinik I für Innere Medizin Zentrum für Klinische Studien BMBF 01KN0706, Koln, Germany
    Haematologica 94:113-22. 2009
    ..Fluconazole 400 mg/d is recommended in allogeneic stem cell recipients until development of graft versus host disease only (Level A I). Aerosolized liposomal amphotericin B is recommended during prolonged neutropenia (Level B II)...
  15. doi request reprint Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, 50924 Köln, Germany
    J Antimicrob Chemother 61:939-46. 2008
    ..This study determines risk factors for recurrent IFI in leukaemia patients...
  16. doi request reprint Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
    Oliver A Cornely
    Department I for Internal Medicine, ZKS Köln BMBF 01KN1106, University of Cologne, Cologne, Germany
    Eur J Haematol 87:289-301. 2011
    ....
  17. doi request reprint Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients
    Maria J G T Rüping
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Koln, Germany
    Mycoses 54:230-3. 2011
    ..Future investigations might aim at identifying drug level thresholds that allow for minimum toxicity and optimum efficacy of antifungal prophylaxis...
  18. doi request reprint Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood
    Fedja Farowski
    Universitätsklinikum Köln, Klinik I fur Innere Medizin, Koln, Germany
    Int J Antimicrob Agents 39:228-31. 2012
    ..In vitro data showed that intracellular uptake of micafungin by PBMCs depends on the albumin concentration of the surrounding medium, but only at non-physiological protein concentrations...
  19. ncbi request reprint Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia
    Oliver A Cornely
    Department of Internal Medicine I, Klinikum der Universität zu Köln, Koln, Germany
    Int J Hematol 79:74-8. 2004
    ..A larger phase III trial is warranted to further evaluate the lack of inferiority of the oral monotherapy regimen versus standard intravenous therapy...
  20. ncbi request reprint A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, 50937 Koln, Germany
    J Infect 55:445-9. 2007
    ..We conducted a trial to analyze the efficacy and safety of voriconazole in the prevention of lung infiltrates during induction chemotherapy for acute myelogenous leukaemia (AML)...
  21. doi request reprint Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry
    Jörg J Vehreschild
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany
    Int J Antimicrob Agents 34:446-50. 2009
    ..Despite antifungal prophylaxis, risk of breakthrough IFD was high in both groups...
  22. ncbi request reprint Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit II for Infectious Diseases, Hospital of the University of Cologne, Koln, Germany
    Leuk Lymphoma 51:20-6. 2010
    ....
  23. pmc Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum 2 für Infektiologie, Koln, Germany
    Antimicrob Agents Chemother 54:1815-9. 2010
    ..8%. The method was established as standard practice for the quantitation of intracellular antifungal concentrations and optimizes TDM by applying a rapid single method for 6 antifungals...
  24. pmc Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Studienzentrum Infektiologie II, Kerpener Strasse 62, Koln, Germany
    Int J Hematol 87:126-31. 2008
    ..Data from this survey demonstrate the difficulty of putting drugs to their approved use in IFI...
  25. pmc Intracellular concentrations of posaconazole in different compartments of peripheral blood
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum 2 für Infektiologie, Fedja Farowski, MSc, 50924 Cologne, Germany
    Antimicrob Agents Chemother 54:2928-31. 2010
    ..Posaconazole reaches high concentrations within human PBMCs and PMNs and is, to a lesser extent, present in RBCs. The high intracellular concentrations might contribute to posaconazole efficacy and distribution...
  26. doi request reprint Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients
    Jörg J Vehreschild
    Hospital of the University of Cologne, Department I of Internal Medicine, Clinical Trials Unit II for Infectious Diseases BMBF 01KI0771, Kerpener Strasse 62, 50937 Koln, Germany
    Expert Opin Pharmacother 11:95-113. 2010
    ..There is an ongoing discussion on whether these studies may be applied to transplant patients as well...
  27. ncbi request reprint Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    Oliver A Cornely
    1st Dept of Internal Medicine, University of Cologne, Germany
    Clin Infect Dis 44:1289-97. 2007
    ..Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking...
  28. doi request reprint Mucormycosis treated with posaconazole: review of 96 case reports
    Joerg J Vehreschild
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    Crit Rev Microbiol 39:310-24. 2013
    ..Overall mortality was 24% (lacking data for three patients). In published case reports on posaconazole treatment for mucormycosis, the drug was frequently and successfully used in combination or as second line therapy. ..
  29. ncbi request reprint Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    N Engl J Med 356:348-59. 2007
    ..Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections...
  30. ncbi request reprint Antifungal treatment strategies in high risk patients
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of University of Cologne, Koln, Germany
    Mycoses 51:46-51. 2008
    ..may be switched to fluconazole. Caspofungin or micafungin might be preferred to anidulafungin in the neutropenic patient. L-AmB is a valuable second line treatment option for both groups of patients...
  31. ncbi request reprint Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation
    Jörg J Vehreschild
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    Mycoses 49:42-7. 2006
    ..Symptoms rapidly resolved under posaconazole 200 mg q.i.d. treatment and the patient was able to undergo allogeneic haematopoietic stem cell transplantation on secondary prophylaxis with posaconazole...
  32. ncbi request reprint Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, Cologne, Germany
    Blood 101:3365-72. 2003
    ..The objective of this review of 50 studies accumulating more than 9000 patients is to assess evidence-based criteria with regard to the efficacy of antifungal prophylaxis in neutropenic cancer patients...
  33. doi request reprint Intracellular concentrations of anidulafungin in different compartments of the peripheral blood
    Fedja Farowski
    Department of Internal Medicine, University of Cologne, Cologne, Germany
    Int J Antimicrob Agents 41:379-82. 2013
    ..In vitro data showed that intracellular uptake of anidulafungin by PBMCs depends on the albumin concentration of the surrounding medium, but only at low, i.e. non-physiological, protein concentrations...
  34. ncbi request reprint Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum Infektiologie II, Koln, Germany
    Future Microbiol 1:161-70. 2006
    ..More controlled and sufficiently scaled trials are imperative in order to establish micafungin as a reliable and safe option in clinical practice...
  35. ncbi request reprint Patients at high risk of invasive fungal infections: when and how to treat
    Maria J G T Rüping
    Department I of Internal Medicine, Clinical Trials Unit Infectious Diseases II, Hospital of the University of Cologne, Cologne, Germany
    Drugs 68:1941-62. 2008
    ..Early diagnosis of IFIs is imperative to facilitate treatment success. In all patients at risk for IFIs, blood cultures, galactomannan antigen and diagnostic imaging should be rigorously enforced...
  36. doi request reprint Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial
    J Janne Vehreschild
    Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Int J Antimicrob Agents 39:130-4. 2012
    ..Moxifloxacin prevented bacteraemia and shortened febrile episodes in patients receiving autologous PBSCT. No significant increase of adverse events in the moxifloxacin arm was observed, possibly due to the rather small sample size...
  37. ncbi request reprint Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50931, Koln, Germany
    Ann Hematol 82:S186-200. 2003
    ..The objective of this review accumulating information on about 10.000 patients is to assess evidence based criteria primarily regarding the efficacy of antifungal prophylaxis in neutropenic cancer patients...
  38. ncbi request reprint Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology
    Daniela Tacke
    Klinik I fur Innere Medizin, Uniklinik Köln, Koln, Germany
    Ann Hematol 93:1449-56. 2014
    ..Aerosolised liposomal amphotericin B inhalation in conjunction with fluconazole can be used in patients with prolonged neutropenia (BII). ..
  39. ncbi request reprint Anidulafungin--state of affairs from a clinical perspective
    Jörg J Vehreschild
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinische Infektiologie, Kerpener Strasse, Koln, Germany
    Mycoses 50:38-43. 2007
    ..Future investigations may elucidate how anidulafungin performs clinically in comparison with the other echinocandins...
  40. ncbi request reprint Is there a role for polyenes in treating invasive mycoses?
    Oliver A Cornely
    First Department of Internal Medicine, Hematology Oncology Infectious Diseases, University Hospital of Cologne, Koln, Germany
    Curr Opin Infect Dis 19:565-70. 2006
    ..In addition to re-examining the landmark clinical trials of the past, the more recent findings are put into perspective. The past year has been particularly rich in clinical trials...
  41. doi request reprint Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
    Oliver A Cornely
    Klinik I für Innere Medizin der Universität zu Köln, and Zentrum für Klinische Studien BMBF 01KN0706, Koln, Germany
    Mycoses 54:e838-47. 2011
    ..Further prospective trials are recommended to evaluate comparative outcomes with a primary focus on patients with malignancies and invasive candidiasis...
  42. ncbi request reprint Posaconazole: a next-generation triazole antifungal
    Fedja Farowski
    Klinikum der Universität zu Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum Schwerpunkt Infektiologie II, Koln, Germany
    Future Microbiol 2:231-43. 2007
    ....
  43. ncbi request reprint Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis
    Maria J G T Vehreschild
    First Department of Internal Medicine, University of Cologne, Cologne, Germany German Centre for Infection Research DZIF, partner site Bonn Cologne, Germany Electronic address
    Biol Blood Marrow Transplant 20:823-8. 2014
    ..A follow-up study, assessing the effect of an antibiotic stewardship intervention to decrease the administration of carbapenems in hematological high-risk patients, is warranted...
  44. ncbi request reprint Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study
    Hilmar Wisplinghoff
    Institute for Medical Microbiology, Immunology and Hygiene, and Department of Internal Medicine, University of Cologne, Cologne, Germany
    Infect Control Hosp Epidemiol 24:905-11. 2003
    ..To examine the clinical and epidemiologic features, excess length of stay, extra costs, and mortality attributable to bloodstream infection (BSI) in neutropenic patients with hematologic malignancies...
  45. doi request reprint Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis
    Sebastian M Heimann
    1st Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Mycoses 57:90-7. 2014
    ..3) min. In our hospital, primary antifungal prophylaxis by posaconazole was cost-effective. There was a trend towards cost savings, which was primarily caused by a shorter overall length of stay and the less frequent ICU treatment. ..
  46. doi request reprint Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    Mycoses 57:79-89. 2014
    ..Micafungin, caspofungin and liposomal amphotericin B exhibit favourable treatment response rates that are comparable for patients infected with different Candida spp. ..
  47. ncbi request reprint Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman
    Thomas Elter
    1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany
    Int J Antimicrob Agents 28:262-5. 2006
    ..Furthermore, for the first time, voriconazole levels in an intracerebral abscess were measured in this patient undergoing voriconazole oral therapy...
  48. ncbi request reprint HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases
    Carsten Müller
    Department of Pharmacology, University Hospital Cologne, Cologne, Germany
    Mycoses 49:17-22. 2006
    ..Oral bioavailability was especially low in patients with cytostatic therapy and/or bone marrow transplantation. Further studies are needed to establish the therapeutic range of the posaconazole concentrations...
  49. ncbi request reprint Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort
    J J Vehreschild
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Koln, Germany
    J Antimicrob Chemother 65:1466-71. 2010
    ..However, the value of prophylaxis has been questioned in centres with a low incidence of invasive fungal diseases (IFDs) and pre-emptive treatment strategies...
  50. ncbi request reprint Invasive candidiasis and candidemia: from current opinions to future perspectives
    Maria J G T Rueping
    Clinical Trials Unit Infectious Diseases II and Clinical Trials Center Cologne, Kerpener Strasse 62, Koeln, Germany
    Expert Opin Investig Drugs 18:735-48. 2009
    ..Finally, the reader is provided with a brief overview on promising clinical trial designs and antifungals that might shape the treatment of invasive candidiasis in the years to come...
  51. doi request reprint Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases
    Oliver A Cornely
    University of Cologne, Clinical Trials Centre Cologne ZKS Köln, BMBF 01KN0706, Germany
    Expert Opin Drug Saf 10:171-83. 2011
    ..To define better the safety profile of micafungin, an analysis of micafungin clinical trial safety data was undertaken...
  52. doi request reprint Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT
    Maria J G T Rüping
    Uniklinik Köln, Klinik I fur Innere Medizin, Koln, Germany
    Support Care Cancer 19:1211-6. 2011
    ....
  53. ncbi request reprint Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Gerd Fatkenheuer
    Klinik 1 für Innere Medizin, Klinikum der Universität zu Köln, 50924, Koln, Germany
    Ann Hematol 82:S149-57. 2003
    ..In the future, the rate of catheter-related infections in neutropenic patients may be reduced by the use of catheters coated with antimicrobial agents...
  54. doi request reprint Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab
    Thomas Elter
    Department of Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Ann Hematol 88:121-32. 2009
    ..In this review article, we provide an overview of common infectious events associated with alemtuzumab therapy in CLL. We also discuss recommendations for effectively monitoring and managing infections in CLL patients...
  55. pmc Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation
    V Kohl
    Department of Pharmacology, University of Cologne, Cologne, Germany
    Antimicrob Agents Chemother 54:207-12. 2010
    ..Corresponding adjustments of the starting dose according to the presence of diarrhea and according to age appear to be justified before TDM results are available...
  56. ncbi request reprint Our 2014 approach to mucormycosis
    Daniela Tacke
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Mycoses 57:519-24. 2014
    ..In patients with stable disease we switch to posaconazole 200 mg four times per day. In case of progression antifungal combination is an option. ..
  57. ncbi request reprint Fungal endocarditis
    Daniela Tacke
    a1st Department of Internal Medicine, University Hospital of Cologne bZentrum für Klinische Studien BMBF 01KN1106, cCologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany Daniela Tacke and Philipp Koehler contributed equally to the writing of this article
    Curr Opin Infect Dis 26:501-7. 2013
    ..In this review we provide up-to-date information on treatment recommendations, and discuss recent case reports on fungal endocarditis and challenges in prophylaxis and treatment...
  58. ncbi request reprint Aspergillosis of bones and joints - a review from 2002 until today
    Philipp Koehler
    1st Department of Internal Medicine, University Hospital of Cologne, Zentrum für Klinische Studien BMBF 01KN1106, CECAD Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, Cologne, Germany
    Mycoses 57:323-35. 2014
    ..Properly established treatment guidelines and prophylaxis for patients at risk are required as the high mortality rate continues to pose a future challenge. ..
  59. doi request reprint Anidulafungin: advantage for the newcomer?
    Maria J Rüping
    Uniklinik Köln, Klinik I fur Innere Medizin, Klinisches Studienzentrum, Schwerpunkt Infektiologie II, Bachemer Str 86, 50931 Koln, Germany
    Expert Rev Clin Pharmacol 1:207-16. 2008
    ..Significant differences in clinical efficacy or safety favoring anidulafungin over the other echinocandins are yet to be discovered. ..
  60. ncbi request reprint Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany
    O A Cornely
    Klinikum der Universitat, Kerpener Strasse 62, 50924, Koln, Germany
    Curr Med Res Opin 24:1743-53. 2008
    ..To investigate the economic impact of micafungin (MICA) for treatment of invasive candidiasis and candidaemia (systemic Candida infections), a health economic analysis was conducted comparing MICA with liposomal amphotericin B (L-AMB)...
  61. ncbi request reprint Forty-one recent cases of invasive zygomycosis from a global clinical registry
    M J G T Rüping
    1st Department of Internal Medicine, University of Cologne, Cologne, Germany
    J Antimicrob Chemother 65:296-302. 2010
    ..Invasive zygomycosis accounts for a significant proportion of all invasive fungal diseases (IFD), but clinical data on the clinical course and treatment response are limited...
  62. ncbi request reprint Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression
    Clara Lehmann
    1st Department of Internal Medicine, University of Cologne, Germany
    Curr HIV Res 6:555-9. 2008
    ..This treatment strategy may represent an option for patients with poor immunologic responses to antiretroviral therapy despite undetectable viremia...
  63. ncbi request reprint A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation
    O A Cornely
    Department I of Internal Medicine, Hematology, Oncology and Infectious Diseases, University of Cologne, Cologne, Germany
    Bone Marrow Transplant 28:899-901. 2001
    ..This case report describes a novel form of aspergillosis and underlines the need for an aggressive diagnostic approach in severely immunocompromised patients...
  64. ncbi request reprint Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B
    A Rothe
    Klinik I fur Innere Medizin, Universitat zu Koln, Joseph Stelzmann Str 9, 50931 Cologne, Germany
    Ann Hematol 83:394-7. 2004
    ..The combination therapy described here represents a novel approach to the treatment of Fusarium spp. in the immunocompromised host in whom Fusarium spp. are known to cause disseminated infection with high mortality...
  65. ncbi request reprint Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia
    K Hubel
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Int J Hematol 79:289-92. 2004
    ..This case report describes the successful treatment of CDC during neutropenia using combination antifungal therapy and suggests controlled studies to establish optimal therapeutic strategies...
  66. ncbi request reprint The first echinocandin: caspofungin
    O A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, 50924 Köln, Germany
    Mycoses 45:56-60. 2002
    ..Reports of combination therapy or highly effective antifungal treatment (HEAT) in limited patient numbers are promising. New trials of combination therapy are warranted...
  67. pmc Disseminated Neocosmospora vasinfecta infection in a patient with acute nonlymphocytic leukemia
    O A Cornely
    Klinik I fur Innere Medizin, Universitätsklinik Köln, 50924 Köln, Germany
    Emerg Infect Dis 7:149-52. 2001
    ..N. vasinfecta, a plant pathogen, was identified by culture and genetic sequencing. Susceptibility testing revealed in vitro resistance for common antifungals...
  68. ncbi request reprint Failure of anti-infective mouth rinses and concomitant antibiotic prophylaxis to decrease oral mucosal colonization in autologous stem cell transplantation
    H Lövenich
    Universität Koeln, Klinik I fur Innere Medizin, Koeln, Germany
    Bone Marrow Transplant 35:997-1001. 2005
    ..Since 90% of our patients had febrile neutropenia at some time point during the observation period, the approach evaluated cannot be recommended as prophylaxis of febrile neutropenia as such...
  69. ncbi request reprint Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
    Ernst Rüdiger Kuse
    Klinik für Viszeral und Transplantationschirurgie, Hannover, Germany
    Lancet 369:1519-27. 2007
    ..Invasive candidosis is increasingly prevalent in seriously ill patients. Our aim was to compare micafungin with liposomal amphotericin B for the treatment of adult patients with candidaemia or invasive candidosis...
  70. doi request reprint Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death
    Oliver A Cornely
    Clin Infect Dis 46:1626-7; author reply 1627-8. 2008
  71. ncbi request reprint [Current development in the diagnostics and therapy of systemic fungal infections in cancer patients]
    Meinolf Karthaus
    Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Johannes Krankenhaus, Bielefeld, Deutschland
    Wien Med Wochenschr 154:199-208. 2004
    ..Recent developments in the epidemiology, diagnostics and treatment of fungal infections are reviewed and discussed in the context of the current state of art for the management of invasive fungal infections in cancer patients...
  72. ncbi request reprint Improved outcome in central nervous system aspergillosis, using voriconazole treatment
    Stefan Schwartz
    Medizinische Klinik III, Hämatologie, Onkologie und Transfusionsmedizin, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Blood 106:2641-5. 2005
    ..We conclude from this large cohort of patients that voriconazole treatment together with neurosurgical management, whenever feasible, is currently the best approach to treat patients with CNS aspergillosis...
  73. ncbi request reprint Choosing a study population for the evaluation of antifungal prophylaxis
    Oliver A Cornely
    Clin Infect Dis 40:1699; author reply 1699-701. 2005
  74. ncbi request reprint Recent developments in the management of invasive fungal infections in patients with hematological malignancies
    Meinolf Karthaus
    Medizinische Klinik II, Evangelisches Johannes Krankenhaus, Schildescher Strasse 99, 33611 Bielefeld, Germany
    Ann Hematol 84:207-16. 2005
    ..This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients...
  75. ncbi request reprint Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia
    Thomas J Walsh
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 351:1391-402. 2004
    ..Caspofungin, a member of the new echinocandin class of compounds, may be an effective alternative that is better tolerated than amphotericin B...
  76. ncbi request reprint Itraconazole versus fluconazole for antifungal prophylaxis
    Meinolf Karthaus
    Ann Intern Med 140:579-80; author reply 581-2. 2004
  77. ncbi request reprint Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies
    Oliver A Cornely
    J Antimicrob Chemother 57:151-2; author reply 152-4. 2006
  78. ncbi request reprint Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Value Health 9:12-23. 2006
    ..To assess the costs and cost-effectiveness of voriconazole in comparison to conventional amphotericin B (CAB) for the treatment of invasive aspergillosis in Germany...
  79. ncbi request reprint [Echinocandins in invasive candidiasis]
    Andreas Glöckner
    Neurologisches Rehabilitationszentrum, Greifswald
    Med Klin (Munich) 103:397-405. 2008
    ....
  80. pmc Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
    Peter Kaskel
    Outcomes Research, MSD Sharp and Dohme GmbH, Haar, Germany
    Ann Hematol 87:311-9. 2008
    ..The data presented in this scenario show that use of caspofungin in hematology-oncology departments in Germany results in shorter hospital stays and is at least cost-neutral compared to use of L-AmB...
  81. ncbi request reprint Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients
    Georg Maschmeyer
    Department of Internal Medicine, Hematology and Oncology, Klinikum Ernst von Bergmann, Potsdam, Germany
    Drugs 67:1567-601. 2007
    ..Voriconazole prophylaxis may be suitable for prevention of IA as well; however, the results of large clinical trials are still awaited...
  82. ncbi request reprint Zygomycosis--current epidemiological aspects
    Andreas Glöckner
    Neurologisches Rehabilitationszentrum, Greifswald, Germany
    Mycoses 50:50-5. 2007
    ..Currently recruiting multicentre trials on primary prophylaxis of IFI will have to show the preventive effectiveness of antifungals with mould activity and the incidence of zygomycosis under prospectively controlled conditions...
  83. ncbi request reprint Treatment options in candidaemia
    Meinolf Karthaus
    Department Hematology Oncology and Palliative Care, Ev Krankenhaus Bielefeld, Med Klinik im Johannesstift, Schildescher Strasse, Bielefeld
    Mycoses 50:44-9. 2007
    ..With the advent of new antifungals the efficacy and safety of antifungal treatment have been improved substantially. This review summarises the new treatment options in candidaemia...
  84. ncbi request reprint Antifungal prophylaxis for invasive mycoses in high risk patients
    Andrew J Ullmann
    Third Department of Internal Medicine, Klinikum der Johannes Gutenberg Universitat, Mainz, Germany
    Curr Opin Infect Dis 19:571-6. 2006
    ..The purpose of this article is to review recent studies in patient populations at high risk for invasive fungal infections...
  85. ncbi request reprint Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006
  86. ncbi request reprint Second-line treatment in invasive mould infections
    Meinolf Karthaus
    Medizinische Klinik II, Onkologie und Palliativmedizin, Evangelisches Krankenhaus Bielefeld, Med Klinik Hämatologie Onkologie und Palliativmedizin im Johannesstift, Bielefeld, Germany
    Mycoses 49:23-6. 2006
    ..This review highlights the new treatment options for the salvage setting in the context of the state-of-the-art management of IFI in cancer patients...
  87. ncbi request reprint Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections
    Issam I Raad
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Infect Dis 42:1726-34. 2006
    ..Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed...
  88. ncbi request reprint Voriconazole versus liposomal amphotericin B for empirical antifungal therapy
    Andrew J Ullmann
    N Engl J Med 346:1745-7; author reply 1745-7. 2002